Skip to main content
PMC home page
Springer Nature - PMC COVID-19 Collection logoLink to Springer Nature - PMC COVID-19 Collection
. 1992;21(2):214–220. doi: 10.1007/BF02591649

Changes in the coagulation-fibrinolysis balance of endothelial cells and mononuclear phagocytes: role in disseminated intravascular coagulation associated with infectious diseases

Nicola Semeraro 1,✉, Mario Colucci 1
PMCID: PMC7102176  PMID: 1591371

Summary

Over the last few years, evidence has accumulated that the pathogenetic mechanism of disseminated intravascular coagulation encountered in patients with infectious diseases is extraordinarily complex and involves multiple interactions between the microorganism itself and/or a number of mediators, both microorganism derived and host manufactured, and multifunctional cellular systems, namely endothelial cells and mononuclear phagocytes. In particular, infectious agents and mediators shift the coagulation-fibrinolysis equilibrium of these cells towards fibrin formation and accumalation, via enhancement of procoagulant and fibrinolytic capacities. New insights into the pathogenetic mechanism may have important implications for the management of infected patients with disseminated intravascular coagulation.

Key words: Disseminated intravascular coagulation, Infection, Coagulation-fibrinolysis, Endothelial cells, Mononuclear phagocytes

References

  • 1.Almdahl SM, Brox JH, Osterud B. Mononclear phagocyte thromboplastin and endotoxin in patients with secondary peritonities. Scand J Gastroenterol. 1987;22:914–914. doi: 10.3109/00365528708991935. [DOI] [PubMed] [Google Scholar]
  • 2.Astedt B, Lecander I, Ny T. The placental type plasminogen activator inhibitor, PAI-2. Fibrinolysis. 1987;1:203–203. doi: 10.1016/0268-9499(87)90037-3. [DOI] [Google Scholar]
  • 3.Bachman F. Fibrinolysis. In: Verstraete M, Vermylen J, Lijnen HR, Arnout J, editors. Thrombosis and haemostasis. Leuven: Leuven University Press; 1987. pp. 227–265. [Google Scholar]
  • 4.Bauer KA, ten Cate H, Barzegar S, Springgs DR, Sherman ML, Rosenberg RD. Tumor necrosis factor infusions have a procoagulant effect on the hemostatic mechanism in humans. Blood. 1989;74:165–165. [PubMed] [Google Scholar]
  • 5.Baumgartner JD. Monoclonal anti-endotoxin antibodies for the treatment of gram-negative bacteremia and septic shock. Eur J Clin Microbiol Infect Dis. 1990;9:711–711. doi: 10.1007/BF02184682. [DOI] [PubMed] [Google Scholar]
  • 6.Bevilacqua MP, Pober JS, Majeau GR, Fiers W, Cotran R, Gimbrone M. Recombinant tumor necrosis factor induces procoagulant activity in cultured human vascular endothelium: characterization and comparison with the actions of interleukin-1. Proc Natl Acad Sci USA. 1986;83:4533–4533. doi: 10.1073/pnas.83.12.4533. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 7.Blasi F. Surface receptors for urokinase plasminogen activator. Fibrinolysis. 1988;2:73–73. doi: 10.1016/0268-9499(88)90370-0. [DOI] [Google Scholar]
  • 8.Brandtzaeg P, Joo GB, Brusletto B, Kierulf P. Plasminoge activator inhibitor 1 and 2, alpha-2-antiplasmin, plasminogen, and endotoxin levels in systemic meningococcal disease. Thromb Res. 1990;57:271–271. doi: 10.1016/0049-3848(90)90326-8. [DOI] [PubMed] [Google Scholar]
  • 9.Brukman J, Wiggins RC. Procoagulant activity in kidneys of normal and bacterial lipopolysaccharide-treated rabbits. Kidney Int. 1987;32:31–31. doi: 10.1038/ki.1987.168. [DOI] [PubMed] [Google Scholar]
  • 10.Castellote JC, Grau E, Linde MA, Pujol-Moix N, Rutllant MLI. Detection of both type 1 and type 2 plasminogen activator inhibitors in human monocytes. Thromb Haemost. 1990;63:67–67. [PubMed] [Google Scholar]
  • 11.Chapman HA, Vavrin Z, Hibbs JB., Jr Coordinate expression of macrophage procoagulant and fibrinolytic activity in vitro and in vivo. J Immunol. 1983;130:261–261. [PubMed] [Google Scholar]
  • 12.Chapman HA, Yang X, Sailor LZ, Sugarbaker DJ. Developmental expression of plasminogen activator inhibitor type 1 by human alveolar macrophages. J Immunol. 1990;145:3398–3398. [PubMed] [Google Scholar]
  • 13.Colman RV. Contact system in infectious disease. Rev Infect Dis. 1989;11(Suppl 4):689–689. doi: 10.1093/clinids/11.supplement_4.s689. [DOI] [PubMed] [Google Scholar]
  • 14.Colucci M, Balconi G, Lorenzet R, Pietra A, Locati D, Donati MB, Semeraro N. Cultured human endothelial cells generate tissue factor in response to endotoxin. J Clin Invest. 1983;71:1893–1893. doi: 10.1172/JCI110945. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 15.Colucci M, Paramo JA, Collen D. Generation in plasma of a fast-acting inhibitor of plasminogen activator in response to endotoxin stimulation. J Clin Invest. 1985;75:818–818. doi: 10.1172/JCI111777. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 16.Colucci M, Paramo JA, Stassen JM, Collen D. Influence of the fast-acting inhibitor of plasminogen activator on in vivo thrombolysis induced by tissue plasminogen activator in rabbits. J Clin Invest. 1986;78:138–138. doi: 10.1172/JCI112543. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 17.Colucci M, Altomare DF, Chetta G, Triggiani R, Cavallo LG, Semeraro N. Impaired fibrinolysis in obstructive jaundice. Evidence from clinical and experimental studies. Thromb Haemost. 1988;60:25–25. [PubMed] [Google Scholar]
  • 18.Conkling PR, Chua CC, Nadler P, Greenberg CS, Doty E, Misukonis MA, Haney AF, Bast RC, Jr, Weinberg JB. Clinical trials with human tumor necrosis factor: in vivo and in vitro effects on human mononuclear phagocyte function. Cancer Res. 1988;48:5604–5604. [PubMed] [Google Scholar]
  • 19.Conkling PR, Greenberg CS, Weinberg JB. Tumor necrosis factor induces tissue factor-like activity in human leukemia cell line U937 and peripheral blood monocytes. Blood. 1988;72:128–128. [PubMed] [Google Scholar]
  • 20.Dejana E, Breviario F, Erroi A, Bussolino F, Mussoni L, Gramse L, Pintucci G, Casali B, Dinarello LA, van Damme J, Mantovani A. Modulation of endothelial cell functions by different molecular species of interleukin 1. Blood. 1987;69:695–695. [PubMed] [Google Scholar]
  • 21.Drake TA, Morissey JW, Edgington TS. Selective cellular expression of tissue factor in human tissues. Am J Pathol. 1989;134:1087–1087. [PMC free article] [PubMed] [Google Scholar]
  • 22.Drancourt M, Alessi MC, Levy PY, Juhan-Vague I, Raoult D. Secretion of tissue-type plasminogen activator and plasminogen activator inhibitor byRickettsia conorii- andRickettsia rickettsii-infected cultured endothelial cells. Infect Immun. 1990;58:2459–2459. doi: 10.1128/iai.58.8.2459-2463.1990. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 23.Edgington TS, Machman N, Brand K, Ruf W. The structural biology of expression and function of tisdue factor. Thromb Haemost. 1991;66:67–67. [PubMed] [Google Scholar]
  • 24.Edwards RL, Rickles FR. Macrophage procoagulants. In: Spaet TH, editor. Progress in hemostasis and thrombosis, vol. 7. New York: Grune & Stratton; 1984. pp. 183–201. [PubMed] [Google Scholar]
  • 25.Estelles A, Andres C, Gilabert J, Espana F, Hendl S, Aznar J. Inibidores de los activadores del plasminogeno (PAI-1 y PAI-2). Aspectos fisiopatologicos. Rev Iberoamer Tromb Hemostassia. 1989;3–4:18–18. [Google Scholar]
  • 26.Fong Y, Lowry SF. Tumor necrosis factor in the pathophysiology of infection and sepsis. Clin Immunol Immunopathol. 1990;55:157–157. doi: 10.1016/0090-1229(90)90094-7. [DOI] [PubMed] [Google Scholar]
  • 27.Garner R, Evensen SA. Endotoxin-induced intravascular coagulation and shock in dogs: the role of factor VII. Br J Haematol. 1974;27:655–655. doi: 10.1111/j.1365-2141.1974.tb06632.x. [DOI] [PubMed] [Google Scholar]
  • 28.Hamilton KK, Hattori R, Esmon CT, Sims PJ. Complement proteins C5b-9 induce vesiculations of the endothelial plasma membrane and expose catalytic surface for assembly of the prothrombinase enzyme complex. J Biol Chem. 1990;265:3809–3809. [PubMed] [Google Scholar]
  • 29.van Hinsberg VWM. Regulation of the synthesis and secretion of plasminogen activators by endothelial cells. Haemostasis. 1988;18:307–307. doi: 10.1159/000215814. [DOI] [PubMed] [Google Scholar]
  • 30.van Hinsberg VWM, Kooistra T, van den Berg EA, Princen HMG, Fiers W, Emeis JJ. Tumor necrosis factor increases the production of plasminogen activator inhibitor in human endothelial cells in vitro and in rats in vivo. Blood. 1988;72:1467–1467. [PubMed] [Google Scholar]
  • 31.Hofmann H, Mahn I, Muller-Berghaus G. The generation of microclots from circulating soluble Des-A fibrin. Thromb Haemost. 1979;42:39a–39a. [Google Scholar]
  • 32.Idell S, James KK, Levin EG, Schwartz BS, Manchanda N, Maunder RJ, Martin TR, McLarty J, Fair DS. Local abnormalities in coagulation and fibrinolytic pathways predispose to alveolar fibrin deposition in adult respiratory distres syndrome. J Clin Invest. 1989;84:695–695. doi: 10.1172/JCI114217. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 33.Kobayashi M, Shimada K, Onawa T. Human recombinant interleukin 1β- and tumor necrosis factor α-mediated suppression of heparin-like compounds on cultured porcine aortic endothelial cells. J Cell Physiol. 1990;144:383–383. doi: 10.1002/jcp.1041440304. [DOI] [PubMed] [Google Scholar]
  • 34.Krishnamurti C, Barr CF, Hassett MA, Young GD, Alving BM. Plasminogen activator inhibitor: a regulator of ancrod-induced fibrin deposition in rabbits. Blood. 1987;69:798–798. [PubMed] [Google Scholar]
  • 35.Krishnamuri T, Alving B. Effect of dengue virus on procoagulant and fibrinolytic activities of monocytes. Rev Infect Dis. 1989;11(Suppl 4):843–843. doi: 10.1093/clinids/11.supplement_4.s843. [DOI] [PubMed] [Google Scholar]
  • 36.Levy G, Abecassis M. Activation of the immune coagulation system by murine hepatitis virus strain 3. Rev Infect Dis. 1989;11(Suppl 4):712–712. doi: 10.1093/clinids/11.Supplement_4.S712. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 37.Loskutoff DJ, Sawdey M, Mimuro J. Type 1 plasminogen activator inhibitor. In: Coller BS, editor. Progress in hemostasis and thrombosis, vol 9. Philadelphia: Saunders; 1989. pp. 87–115. [PubMed] [Google Scholar]
  • 38.Marder VJ, Martin SE, Francis CV, Colman RV, Salzman EW. Consumptive thrombohemorrhagic disorders. In: Colman RV, Hirsh J, Marder VJ, editors. Hemostasis and thrombosis. Basic principles and clinical practice. Philadelphia: Lippincott; 1987. pp. 975–1015. [Google Scholar]
  • 39.Margaretten W, Zunker HO, McKay DG. Production of the generalized Shwartzman reaction in pregnant rats by intravenous infusion of thrombin. Lab Invest. 1964;13:552–552. [PubMed] [Google Scholar]
  • 40.Moore KL, Andreoli SP, Esmon NL, Esmon CT, Bang NU. Endotoxin enhances tissue factor and suppresses thrombomodulin expression of human vascular endothelium in vitro. J Clin Invest. 1987;79:124–124. doi: 10.1172/JCI112772. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 41.Muller-Berghaus G. The role of platelets, leukoccytes and complement in the activation of intravascular coagulation by endotoxin. In: de Gaetano G, Garattini S, editors. Platelets: a multidisciplinary approach. New York: Raven; 1978. pp. 303–320. [Google Scholar]
  • 42.Niemetz J. The role of leukocytes in thrombosis. In: Colman RV, Hirsh J, Marder VJ, Salzman EW, editors. Hemostasis and thrombosis. Basic principles and clinical practice. Philadelphia: Lippincott; 1987. pp. 1089–1097. [Google Scholar]
  • 43.Ogawa S, Gerlach H, Esposito C, Pasagian-Macaulay A, Brett J, Stern D. Hypoxia modulates the barrier and coagulant function of cultured bovine endothelium. J Clin Invest. 1990;85:1090–1090. doi: 10.1172/JCI114540. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 44.Osterud B, Flaegstad T. Increased thromboplastin activity in monocytes of patients with meningococcal infections: related to unfavourable prognosis. Thromb Haemost. 1983;49:5–5. [PubMed] [Google Scholar]
  • 45.Paramo JA, Perez JL, Serrano M, Rocha E. Types 1 and 2 plasminogen activator inhibitor and tumor necrosis factor alpha in patients with sepsis. Thromb Haemost. 1990;64:3–3. [PubMed] [Google Scholar]
  • 46.van der Poll T, Buller HR, ten Cate H, Wortel CH, Bauer KA, van Deventer SJH, Hack CE, Sauerwein HP, Rosenberg AD, ten Cate JW. Activation of coagulation after administration of TNF to normal subjects. N Engl J Med. 1990;322:1622–1622. doi: 10.1056/NEJM199006073222302. [DOI] [PubMed] [Google Scholar]
  • 47.Pralong G, Calandra T, Glauser MP, Schellekens J, Verhoef J, Bachmann F, Kruithof EKO. Plasminogen activator inhibitor 1: a new prognostic marker in spetic shock. Thromb Haemost. 1989;61:459–459. [PubMed] [Google Scholar]
  • 48.Preissner KT. Anticoagulant potential of endothelial cell membrane components. Haemostasis. 1988;18:271–271. doi: 10.1159/000215813. [DOI] [PubMed] [Google Scholar]
  • 49.Rothberger H, Dove FB, Lee TK, McGee MP, Kardon B. Procoagulant activity of lymphocyte-macrophage populations in rabbits: selective increases in marrow, blood and spleen cells during Shwartzman reactions. Blood. 1983;61:712–712. [PubMed] [Google Scholar]
  • 50.Sawdey M, Podor TJ, Loskutoff DJ. Regulation of type 1 plasminogen activator inhibitor gene expression in cultured bovine aortic endothelial cells. J Biol Chem. 1989;264:10396–10396. [PubMed] [Google Scholar]
  • 51.Scarpati EM, Sadler JE. Regulation of endothelial cell coagulant properties. J Biol Chem. 1989;264:20705–20705. [PubMed] [Google Scholar]
  • 52.Schwartz BS, Monroe MC, Levin EG. Increased release of plasminogen activator inhibitor type 2 accompanies the human mononuclear cell tissue factor response to lipopolysaccharide. Blood. 1989;71:734–734. [PubMed] [Google Scholar]
  • 53.Semeraro N, Biondi A, Lorenzet R, Locati D, Mantovani A, Donati MB. Direct induction of tissue factor synthesis by endotoxin in human macrophages from diverse anatomical sites. Immunology. 1983;50:529–529. [PMC free article] [PubMed] [Google Scholar]
  • 55.Semeraro N, Montermurro P, Rossiello MR, Colucci M, Viero P, Gorini S. Involvement of leukocytes in haemostasis and thrombosis. In: Barbui T, Cortelazzo S, de Gaetano G, editors. Cellular blood components in haemostasis and thrombosis. London: Libbey; 1988. pp. 81–95. [Google Scholar]
  • 56.Semeraro N, Montemurro P, Chetta G, Altomare DF, Giordano D, Colucci M. Increased procoagulant activity of peripheral blood monocytes in human and experimental obstructive jaundice. Gastroenterology. 1989;96:892–892. [PubMed] [Google Scholar]
  • 57.Semeraro N, Montemurro P, Triggiani R, Conese M, Cavallo LG, Colucci M. Endothelial procoagulant and thrombomodulin activity in endotoxin-treated rabbits. Thromb Haemost. 1991;65:794–794. [Google Scholar]
  • 58.Shen SMC, Rapaport SI, Feinstein DI. Intravascular clotting after endotoxin in rabbits with impaired intrinsic clotting produced by a factor VIII antibody. Blood. 1973;42:523–523. [PubMed] [Google Scholar]
  • 59.Silva AT, Bayston KF, Cohen J. Propyylactic and therapeutic effects of a monoclonal antibody to tumor necrosis factor-alpha in experimental gram-negative shock. J Infect Dis. 1990;162:421–421. doi: 10.1093/infdis/162.2.421. [DOI] [PubMed] [Google Scholar]
  • 60.Stern DM, Kaiser E, Nawroth PP. Regulation of the coagulation system by vascular endothelial cells. Haemostasis. 1988;18:202–202. doi: 10.1159/000215808. [DOI] [PubMed] [Google Scholar]
  • 61.Suffredini AF, Harpel PC, Parrillo JE. Promotion and subsequent inhibition of plasminogen activation after administration of intravenous endotoxin to normal subjects. N Engl J Med. 1989;320:1165–1165. doi: 10.1056/NEJM198905043201802. [DOI] [PubMed] [Google Scholar]
  • 62.Taylor FB, Jr, Chang A, Ruf W, Morissey JH, Catlett R, Blick K, Edgington TS. LethalE. coli septic shock is prevented by blocking tissue factor with monoclonal antibody. Circ Shock. 1991;33:127–127. [PubMed] [Google Scholar]
  • 63.Thomas L, Good RA. Studies on the generalized Shwartzman reaction. J Exp Med. 1952;96:605–605. doi: 10.1084/jem.96.6.605. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 64.Van Deventer SJH, Buller HR, Cate ten JW, Aarden LA, Hack CE, Sturk A. Experiment endotoxemia in humans: analysis of cytokine release and coagulation, fibrinolytic and complement pathways. Blood. 1999;76:2520–2520. [PubMed] [Google Scholar]
  • 65.Vercellotti JM. Proinflammatory and procoagulant effects of herpes simplex infection on human endothelium. Blood Cells. 1990;16:209–209. [PubMed] [Google Scholar]
  • 66.Warr TA, Rao LVM, Rapaport SI. Disseminated intravascular coagulation in rabbits induced by administration of endotoxin or tissue factor: effect of anti-tissue factor antibodies and measurement of plasma extrinsic pathway inhibitor activity. Blood. 1990;75:1481–1481. [PubMed] [Google Scholar]
  • 67.Wilcox JN, Smith KM, Schwartz SM, Gordon D. Localization of tissue factor in the normal vessel wall and in the atherosclerotic plaque. Proc Natl Acad Sci USA. 1989;86:2839–2839. doi: 10.1073/pnas.86.8.2839. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 68.Wohlwend A, Belin D, Vassalli JD. Plasminogen activator-specific inhibitor produced by human monocytes macrophages. J Exp Med. 1987;165:320–320. doi: 10.1084/jem.165.2.320. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from International Journal of Clinical & Laboratory Research are provided here courtesy of Nature Publishing Group

RESOURCES